Phase I Study of Vasoactive Intestinal Peptide in Patients With Acute Respiratory Distress Syndrome and Sepsis
Recruitment status was Recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
OBJECTIVES:
I. Determine the maximum tolerated dose of vasoactive intestinal peptide in patients with acute respiratory distress syndrome.
II. Evaluate the safety and pharmacodynamic activity of this peptide in these patients.
| Condition | Intervention | Phase |
|---|---|---|
|
Sepsis Respiratory Distress Syndrome Respiratory Distress Syndrome, Adult |
Drug: vasoactive intestinal peptide |
Phase 1 |
| Study Type: | Interventional |
| Study Design: | Primary Purpose: Treatment |
| Estimated Enrollment: | 18 |
| Study Start Date: | September 1998 |
PROTOCOL OUTLINE:
This is a dose escalation study.
Patients receive vasoactive intestinal peptide (VIP) IV over either 6 or 12 hours.
Cohorts of 3 patients each receive escalating doses of VIP over either 6 or 12 hours until the maximum tolerated dose is determined.
Patients are followed for 30 days.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
PROTOCOL ENTRY CRITERIA:
--Disease Characteristics--
Diagnosis of adult respiratory distress syndrome (ARDS) with sepsis
ARDS characterized by: hypoxemia refractory to supplemental oxygen therapy, diffuse pulmonary infiltrates, no cardiogenic cause of pulmonary edema, and reduced pulmonary compliance
Sepsis characterized by: Two or more of the following: Fever or hypothermia; Tachycardia; Tachypnea; WBC greater than 12,000/mm3 or less than 4,000/mm3 or immature neutrophils; Hypotension; Clinical suspicion of infection; Inadequate organ perfusion or organ dysfunction as demonstrated by: Acute deterioration in mental acuity (excluding sedatives or other nonsepsis causes) OR Unexplained metabolic acidosis OR Oliguria for greater than 2 hours OR Unexplained coagulopathy (elevated PT or PTT or platelet count decreased to less than 50% of baseline within 24 hours or less than 100,000/mm3) OR Acute elevation of bilirubin to greater than 2.0 mg/dL AND elevation of alkaline phosphatase, SGOT, or SGPT
No sepsis with unstable BP
--Prior/Concurrent Therapy--
At least 30 days since prior enrollment in investigational trial; No other concurrent enrollment in investigational trial
--Patient Characteristics--
Hematopoietic: See Disease Characteristics; No uncontrolled hemorrhage (transfusion of 4 or more units required within past 24 hours); No chemotherapy induced neutropenia (granulocyte count less than 1000/mm3)
Hepatic: No severe liver disease with portal hypertension
Renal: No anuria (urine output less than 50 mL/day)
Cardiovascular: No cardiogenic shock
Neurologic: No recent stroke, head trauma, or increased intracranial pressure; No other serious neurologic disorder
Other: Not pregnant; No acquired immune deficiency syndrome; No immunosuppressed transplant patients; No severe burns; No irreversible underlying condition with rapidly fatal course; No marked obesity; No recent history of diarrhea
Contacts and Locations| United States, New York | |
| Veterans Affairs Medical Center - Northport | Recruiting |
| Northport, New York, United States, 11768 | |
| Contact: Sami I. Said 631-444-1754 | |
| State University of New York Health Sciences Center - Stony Brook | Recruiting |
| Stony Brook, New York, United States, 11790-7775 | |
| Contact: Sami I. Said 631-444-1754 | |
| Study Chair: | Sami I. Said | State University of New York |
More Information
No publications provided
| ClinicalTrials.gov Identifier: | NCT00004494 History of Changes |
| Other Study ID Numbers: | 199/14275, SUNY-SB-FDR001488, SUNY-SB-96-077, SUNY-SB-98-2606, FD-R-0001488 |
| Study First Received: | October 18, 1999 |
| Last Updated: | March 7, 2013 |
| Health Authority: | United States: Federal Government |
Keywords provided by Stony Brook University:
|
cardiovascular and respiratory diseases immunologic disorders and infectious disorders neonatal disorders |
rare disease respiratory distress syndrome sepsis |
Additional relevant MeSH terms:
|
Respiratory Distress Syndrome, Newborn Respiratory Distress Syndrome, Adult Acute Lung Injury Respiratory Tract Diseases Systemic Inflammatory Response Syndrome Sepsis Toxemia Lung Diseases Respiration Disorders Infant, Premature, Diseases Infant, Newborn, Diseases Lung Injury Infection |
Inflammation Pathologic Processes Vasoactive Intestinal Peptide Vasodilator Agents Cardiovascular Agents Therapeutic Uses Pharmacologic Actions Gastrointestinal Agents Neuroprotective Agents Protective Agents Physiological Effects of Drugs Central Nervous System Agents |
ClinicalTrials.gov processed this record on May 19, 2013